Research Paper Volume 15, Issue 15 pp 7476—7495
SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC
Figure 5. NSCLC mutational burden according to SETBP1 mutational status. (A) TMB level differences between SETBP1 mutated and wild-type subgroups. (B) A multivariate logistic regression analysis was performed to confirmed the connection between SETBP1 mutations and TMB. (C) NB level differences of SETBP1 two subgroups. (D) TMB and (E) NB level differences between SETBP1 two subgroups based on the data from the TCGA cohort.